For instance, the presence of PD-L1 in several tumour types including lung, renal, gastric and ovarian cancer has been reported to negatively correlate with patients’ prognosis.18–22 Furthermore, a predictive role of PD-L1 expression for clinical response to checkpoint inhibitors has been hypothesised by several studies. Here, CD274 is linked to neoplasm.